Quarterly report pursuant to Section 13 or 15(d)

INTERIM FINANCIAL STATEMENTS (Details)

v3.5.0.2
INTERIM FINANCIAL STATEMENTS (Details) - USD ($)
Jun. 30, 2016
Dec. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Cash and liquid investments $ 16,147,000  
Working capital 15,801,000  
Stockholders' equity 16,018,544 $ 16,070,636
Accumulated deficit 105,858,803 $ 105,582,439
Total value of capitalized patent costs that could be impaired due to inability to locate a new strategic target, a partner or other third-party interested in advancing development and commercial activities of the Venaxis appendicitis portfolio $ 371,000